Photo/SpaceX Livestream

NO.1 SpaceX Starship successfully splashes down in the Indian Ocean

At 8:50 PM Beijing time on June 6, SpaceX's giant Starship rocket launched from Starbase in Boca Chica, Texas, USA, on its fourth flight. The super-heavy booster successfully soft-landed in the Gulf of Mexico, and the Starship itself achieved controlled re-entry and successfully splashed down in the Indian Ocean (Note: refers to the planned landing of artificial satellites, spaceships, etc. in the ocean when they return to Earth). This was the fourth test flight of the Starship, and the previous three had all ended in failure.

Commentary: The successful splashdown of the fourth test flight of SpaceX's Starship demonstrates its continuous progress and innovation in space exploration.

NO.2 ASML to receive "large" 2nm-related orders from TSMC

According to media reports on June 5, Roger Dassen, CFO of Dutch lithography giant ASML, said that the company will start to receive "large" 2nm-related orders from TSMC in the second and third quarters. In addition, Dassen also said in a recent conference call that TSMC and Intel will receive ASML's high-numerical aperture (High-NAEUV) lithography machines this year.

Commentary: ASML's receipt of a large number of 2nm orders from TSMC indicates the semiconductor industry's huge demand for advanced manufacturing technology and also highlights ASML's leading position in the high-end lithography machine market.

NO.3 Is Apple's cooperation with OpenAI an expedient measure? Apple has not given up on developing its own top AI

According to foreign media reports on June 5, in the latest article by well-known whistleblower Mark Gurman, he once again confirmed that Apple will announce a deep cooperation agreement with OpenAI next week. At the same time, Apple has not given up on its dream of developing its own top AI, and will use embodied intelligent robots to set the record straight for the company.

Commentary: Apple's cooperation with OpenAI and its pursuit of embodied intelligent robots show its ambition in the field of artificial intelligence, heralding a new era of human-computer interaction and intelligent technology.

NO.4 Eli Lilly's "weight-loss drug" significantly improves non-alcoholic fatty liver disease

Eli Lilly and Company announced positive results from the SYNERGY-NASH Phase 2 clinical trial of its blockbuster GLP-1 drug tirzepatide (weight-loss drug) for the treatment of patients with metabolic dysfunction-associated non-alcoholic steatohepatitis (MASH) at the European Association for the Study of the Liver (EASL) Annual Meeting this year.In a Phase 2 clinical trial, Lilly said that at 52 weeks, 74% of participants who received the highest dose of tirzepatide achieved an absence of nonalcoholic steatohepatitis (NASH) with no worsening of the liver fibrosis that is a hallmark of this chronic liver disease. By comparison, 12.6% of participants given a placebo met this main study goal. 

Commentary: This drug brings new hope to patients with metabolic dysfunction-associated non-alcoholic steatohepatitis.

Disclaimer: The content and data in this article are for reference only and do not constitute investment advice. Please verify before using.